Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2010, for Zeta Acquisition Corp. II (not Whitehawk Therapeutics, Inc., as indicated in the metadata). The registrant is a Delaware corporation classified as a "shell company" and a "blank check" company in the development stage. Its sole business objective is to investigate and acquire a target company to achieve long-term growth potential. The company has no specific business plan other than to merge with an unidentified company and has generated no revenues since its inception on November 16, 2007.
Key Financial Metrics
| Metric | Value (June 30, 2010) | Value (Dec 31, 2009) |
|---|---|---|
| Cash and Cash Equivalents | $5,760 | $11,142 |
| Total Assets | $11,385 | $13,017 |
| Total Liabilities | $39,863 | $31,613 |
| Stockholders' Deficit | ($28,478) | ($18,596) |
| Notes Payable (Stockholders) | $35,000 | $25,000 |
| Net Loss (6 Months Ended June 30, 2010) | ($9,882) | N/A |
| Cumulative Net Loss (Inception to June 30, 2010) | ($78,478) | N/A |
Liquidity: The company has minimal cash reserves and relies entirely on related party financing. Management states there is no assurance it can satisfy cash requirements for the next twelve months.
Material Changes vs. Prior Period
- Cash Position: Cash and cash equivalents decreased by $5,382 (from $11,142 to $5,760) during the six months ended June 30, 2010, primarily due to operating losses.
- Debt Increase: Notes payable to stockholders increased by $10,000, rising from $25,000 to $35,000. These notes bear 6% interest and are due on demand.
- Operating Loss: The net loss for the six months ended June 30, 2010, was $9,882, compared to $7,032 for the same period in 2009. This increase is attributed to higher general and administrative expenses (legal, accounting, and audit fees).
- Accumulated Deficit: The accumulated deficit grew by approximately $9,882 during the period, reflecting the ongoing burn rate without revenue generation.
Outlook, Risks, and Management Commentary
Going Concern: The financial statements include a substantial doubt about the company's ability to continue as a going concern. The company has no revenues and is dependent on capital investment or financing from related parties to fund operations and pursue a business combination.
Business Plan: Management intends to locate a suitable acquisition candidate within the next 12 months. The company may acquire a financially unstable company or an early-stage entity. There is no assurance that a business combination will be achieved.
Risks:
- Financing Risk: Continued operations depend on obtaining additional funds via equity financing or related party advances, which is not guaranteed.
- Target Risk: Any selected target may be in an early stage of development or financially unstable, carrying inherent operational risks.
- Lack of Diversification: The company anticipates effecting only one business combination, meaning it cannot offset losses from one venture against gains from another.
Unusual Items: The company utilizes office space and equipment of an officer/director at no cost, which management estimates to be de minimis.
Investor Verification Checklist
- Identity Discrepancy: Verify the correct registrant name. The metadata lists "Whitehawk Therapeutics, Inc.," but the filing is for "Zeta Acquisition Corp. II."
- Cash Runway: Confirm current cash levels ($5,760) against upcoming filing and operational costs to assess immediate liquidity risk.
- Related Party Debt: Review the terms of the $35,000 in notes payable to stockholders, specifically the "due on demand" clause and 6% interest rate.
- Acquisition Progress: Investigate if any specific target companies have been identified or if discussions are ongoing, as the filing states no target has been identified.
- Going Concern Status: Assess the likelihood of securing additional financing from related parties given the current stockholder deficit.